Can you recall the initial cancer for keytruda's launch?

What cancer did Keytruda first target?

Keytruda (pembrolizumab) received its first FDA approval in September 2014 for advanced melanoma in patients whose tumors no longer responded to other treatments. The approval came after a phase 1 study showed durable responses in roughly one-quarter of treated patients.

Why was melanoma chosen as the starting indication?

Melanoma was a logical first target because many tumors express PD-1/PD-L1 markers and because existing therapies had limited success. The drug’s ability to block the PD-1 pathway allowed T-cells to remain active against the cancer, a mechanism that showed rapid, measurable tumor shrinkage in early trials.

How did the melanoma approval shape later Keytruda development?

The initial success in melanoma guided the company’s strategy for testing the drug in other PD-L1–expressing tumors. Within two years, approvals expanded to non-small-cell lung cancer and, later, to more than twenty cancer types. The melanoma data also supported the first tissue-agnostic approval based on microsatellite instability-high (MSI-H) status.

Who developed Keytruda and how did patents factor in?

Merck & Co. developed and markets Keytruda. Composition-of-matter patents covering the antibody itself began to expire in the United States around 2028, with additional formulation and use patents extending coverage in some markets. Companies tracking these dates list Keytruda’s key U.S. patents as active until at least 2032 in certain indications. DrugPatentWatch.com

When can biosimilars or competing PD-1 inhibitors reach the market?

Biosimilar versions are not yet approved in the United States, largely because of remaining patent protection. Several other PD-1 and PD-L1 inhibitors—Opdivo, Tecentriq, and Libtayo among them—already compete in overlapping indications and are expected to pressure pricing once Keytruda’s primary patents lapse.